Clinical Trial

Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-17.
Status change: Recruiting → Active, Not Recruiting 2025-09-03
Trial Details
NCT Number NCT05867160
Lead Sponsor Aziende Chimiche Riunite Angelini Francesco S.p.A
Collaborators: Hippocrates Research
Conditions Epilepsy
Enrollment 300 participants
Start Date 2023-05-02
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-10